AllianceBernstein’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

AllianceBernstein’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-43,500	Closed	-$151K	–	3486
2021 Q1	$151K	Hold	43,500	–	–	﹤0.01%	3110
2020 Q4	$146K	Hold	43,500	–	–	﹤0.01%	3058
2020 Q3	$153K	Hold	43,500	–	–	﹤0.01%	3006
2020 Q2	$200K	Buy	+43,500	New	+$193K	﹤0.01%	3006

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

AllianceBernstein's PHAS Position: Q2 2021 in Review

AllianceBernstein sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 43,500 shares — an estimated $151K sold.

AllianceBernstein first reported a position in PHAS in Q2 2020 and held it in 4 quarters. The position peaked at $200K in Q2 2020. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

AllianceBernstein reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 43,500 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $151K.
AllianceBernstein first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
AllianceBernstein's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $200K in Q2 2020.
55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.